Proposed NASDAQ Listing

9 December 2013

Akers Biosciences, Inc.

("ABI"or the "Company")

Proposed NASDAQ Listing

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that further to its previous announcements regarding the proposed listing of the Company's common shares on The NASDAQ Capital Market ("NASDAQ") and the concurrent registered public offering (the "Offering"), the Company filed with the United States Securities and Exchange Commission (the "SEC") an amendment to its Form S-1 related to the proposed Offering on 6 December 2013.

The proposed maximum aggregate offering price under the Offering is $17,250,000. The price per share of the Offering has not yet been established.

These Securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

The Form S-1 submitted by the Company may be viewed on the SEC's website at www.sec.gov 

There are no assurances that the Company will be listed on NASDAQ or that the Offering will proceed.

The Company will update the market on any further progress towards the proposed NASDAQ listing, although marketing is expected to occur in January 2014.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point‐of‐care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Antony Legge or James Thomas

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

*Daniel Stewart & Company plc is not acting for the Company in respect of the Offering.